Calendario›SNY›SanOrg34006

SanOrg34006

Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)

Ensayo de Sanofi en Deep Vein Thrombosis (del registro, en inglés).

Fase

Fase 3

Estado

Completado

Participantes

1.452

previstos

Centros

24

Fin del objetivo primario

sep 2005

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, abierto. Comenzó en may 2003.

Qué mide

symptomatic recurrent pulmonary embolism or deep vein thrombosis within 3 months (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroPatients who have deep vein thrombosis (blood clot in the leg) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood thinning) drug administered once each week, SanOrg34006, with the standard way of treating deep vein thrombosis. The standard treatment includes injections or infusions of an anticoagulant drug (Unfractionated Heparin or low molecular weight heparin) for about a week, followed by vitamin K antagonist (VKA) anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth. Eligible patients will be assigned to treatment with either SanOrg34006 or the combination of Unfractionated Heparin or low molecular weight heparin plus a VKA (warfarin or acenocoumarol) by random chance. Treatment will be known to both patients and their doctors.

Más ensayos de SNY

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00067093), actualizada en abr 2011.